Fibroblast activation protein targeted therapy using [
Actinium
FAPI
Fibroblast activation protein
Lutetium
Pancreatic cancer
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
07
06
2021
accepted:
02
09
2021
pubmed:
20
9
2021
medline:
15
3
2022
entrez:
19
9
2021
Statut:
ppublish
Résumé
Fibroblast activation protein (FAP), which has high expression in cancer-associated fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study used PET scans (1 h post injection) were acquired in PANC-1 xenograft mice (n = 9) after the administration of [ [ This study suggested the possible application of FAPI radioligand therapy in FAP-expressing pancreatic cancer. Further evaluation is necessary to find the best radionuclide with shorter half-life, as well as the combination with therapies targeting tumour cells directly.
Identifiants
pubmed: 34537893
doi: 10.1007/s00259-021-05554-2
pii: 10.1007/s00259-021-05554-2
pmc: PMC8803706
doi:
Substances chimiques
FAPI-46
0
Quinolines
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
871-880Informations de copyright
© 2021. The Author(s).
Références
Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–63.
doi: 10.1002/prca.201300095
Zi F, He J, He D, Li Y, Yang L, Cai Z. Fibroblast activation protein α in tumour microenvironment: recent progression and implications (review). Mol Med Rep. 2015;11:3203–11.
doi: 10.3892/mmr.2015.3197
Wikberg ML, Edin S, Lundberg IV, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol. 2013;34:1013–20.
doi: 10.1007/s13277-012-0638-2
Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.
doi: 10.2967/jnumed.118.210435
Toms J, Kogler J, Maschauer S, et al. Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an (18)F-labeled FAP inhibitor. J Nucl Med. 2020;61:1806–13.
doi: 10.2967/jnumed.120.242958
Lindner T, Altmann A, Krämer S, et al. Design and development of (99m)Tc-labeled FAPI tracers for SPECT imaging and (188)Re therapy. J Nucl Med. 2020;61:1507–13.
doi: 10.2967/jnumed.119.239731
Giesel FL, Kratochwil C, Lindner T, et al. (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–92.
doi: 10.2967/jnumed.118.215913
Kratochwil C, Flechsig P, Lindner T, et al. (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.
doi: 10.2967/jnumed.119.227967
Meyer C, Dahlbom M, Lindner T, et al. Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61:1171–7.
doi: 10.2967/jnumed.119.236786
Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.
doi: 10.2967/jnumed.118.210443
Watabe T, Liu Y, Kaneda-Nakashima K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: (64)Cu- and (225)Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models. J Nucl Med. 2020;61:563–9.
doi: 10.2967/jnumed.119.233122
Giesel FL, Adeberg S, Syed M, et al. FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62:201–7.
doi: 10.2967/jnumed.120.245084
Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421–9.
doi: 10.2967/jnumed.118.224469
Kratochwil C, Giesel FL, Rathke H, et al. [(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. Eur J Nucl Med Mol Imaging. 2021;48(9):3011–3.
doi: 10.1007/s00259-021-05273-8
Nayak T, Norenberg J, Anderson T, Atcher R. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother Radiopharm. 2005;20:52–7.
doi: 10.1089/cbr.2005.20.52
Lyckesvärd MN, Delle U, Kahu H, et al. Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation status. Mutat Res. 2014;765:48–56.
doi: 10.1016/j.mrfmmm.2014.04.005
Lorat Y, Timm S, Jakob B, Taucher-Scholz G, Rübe CE. Clustered double-strand breaks in heterochromatin perturb DNA repair after high linear energy transfer irradiation. Radiother Oncol. 2016;121:154–61.
doi: 10.1016/j.radonc.2016.08.028
Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31.
doi: 10.2967/jnumed.117.191395
Feuerecker B, Tauber R, Knorr K, et al. Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur Urol. 2021;79:343–50.
doi: 10.1016/j.eururo.2020.11.013
Wang Z, Tang Y, Tan Y, Wei Q, Yu W. Cancer-associated fibroblasts in radiotherapy: challenges and new opportunities. Cell Commun Signal. 2019;17:47.
doi: 10.1186/s12964-019-0362-2
Domogauer JD, de Toledo SM, Howell RW, Azzam EI. Acquired radioresistance in cancer associated fibroblasts is concomitant with enhanced antioxidant potential and DNA repair capacity. Cell Commun Signal. 2021;19:30.
doi: 10.1186/s12964-021-00711-4
Ferdinandus J, Eppard E, Gaertner FC, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med. 2017;58:312–9.
doi: 10.2967/jnumed.116.178228
Rasul S, Hacker M, Kretschmer-Chott E, et al. Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur J Nucl Med Mol Imaging. 2020;47:713–20.
doi: 10.1007/s00259-019-04584-1
Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.
doi: 10.1007/s00259-011-1902-1
Kaneda-Nakashima K, Zhang Z, Manabe Y, et al. α-Emitting cancer therapy using (211) At-AAMT targeting LAT1. Cancer Sci. 2020;112(3):1132–40.
doi: 10.1111/cas.14761
Miederer M, Henriksen G, Alke A, et al. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res. 2008;14:3555–61.
doi: 10.1158/1078-0432.CCR-07-4647
Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev. 2008;60:1371–82.
doi: 10.1016/j.addr.2008.04.009
Watabe T, Kaneda-Nakashima K, Ooe K, et al. Extended single-dose toxicity study of [(211)At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer. Ann Nucl Med. 2021;35:702–18.
doi: 10.1007/s12149-021-01612-9
Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56.
doi: 10.1007/s00259-008-0778-1
Gupta SK, Singla S, Bal C. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm. 2012;27:593–9.
doi: 10.1089/cbr.2012.1195